Phase I/II study of a combination of capecitabine, cisplatin, and intraperitonealdocetaxel (XP ID) in patients with advanced gastric cancer with peritoneal metastasis

被引：0
|
作者：
Cho, Hyungwoo
Ryu, Min-Hee
Yoo, Changhoon
Ryoo, Baek-Yeol
Park, Sook Ryun
Kim, Kyu-Pyo
Kim, Beom Su
Yoo, Moon-Won
Yook, Jeong Hwan
Kim, Byung Sik
Kang, Yoon-Koo
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul, South Korea
[5] Asan Med Ctr, Dept Oncol, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.4026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4026
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
    Kim, C.
    Lee, J.
    Choi, Y.
    Kang, B.
    Ryu, M.
    Chang, H.
    Kim, T.
    Kang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
    Chul Kim
    Jae-Lyun Lee
    Yoon Hee Choi
    Byung Woog Kang
    Min-Hee Ryu
    Heung Moon Chang
    Tae Won Kim
    Yoon-Koo Kang
    Investigational New Drugs, 2012, 30 : 306 - 315
  • [33] Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
    Kim, C.
    Lee, J.
    Choi, Y.
    Kang, B.
    Ryu, M.
    Ryoo, B.
    Chang, H.
    Kim, T.
    Kang, Y.
    EJC SUPPLEMENTS, 2009, 7 (02): : 379 - 379
  • [34] Docetaxel and cisplatin in patients with advanced gastric cancer: results of Japanese phase I/II study
    Soh Saitoh
    Yuh Sakata
    Gastric Cancer, 2002, 5 (Suppl 1) : 23 - 26
  • [35] Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: A multicenter phase I/II study
    Mitachi Y.
    Sakata Y.
    Ohtsu A.
    Hyodo I.
    Katsu K.
    Sairenji M.
    Saitoh S.
    Suwa T.
    Sato T.
    Miyata Y.
    Gastric Cancer, 2002, 5 (3) : 160 - 167
  • [36] Phase II study of gemcitabine, capecitabine and cisplatin in patients with advanced pancreatic cancer.
    Chang, HM
    Kim, TW
    Ahn, JH
    Ryu, MH
    Lee, JS
    Kim, WK
    Kang, YK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 368S - 368S
  • [37] Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis
    Kohei Shitara
    Ayako Mizota
    Keitaro Matsuo
    Yozo Sato
    Chihiro Kondo
    Daisuke Takahari
    Takashi Ura
    Masahiro Tajika
    Kei Muro
    Gastric Cancer, 2013, 16 : 48 - 55
  • [38] Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis
    Shitara, Kohei
    Mizota, Ayako
    Matsuo, Keitaro
    Sato, Yozo
    Kondo, Chihiro
    Takahari, Daisuke
    Ura, Takashi
    Tajika, Masahiro
    Muro, Kei
    GASTRIC CANCER, 2013, 16 (01) : 48 - 55
  • [39] Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer
    Taroh Satoh
    Yasuhide Yamada
    Kei Muro
    Hidetoshi Hayashi
    Yasuhiro Shimada
    Daisuke Takahari
    Keisei Taku
    Takako Eguchi Nakajima
    Xiaojin Shi
    Kathryn H. Brown
    Narikazu Boku
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 439 - 446
  • [40] Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer
    Satoh, Taroh
    Yamada, Yasuhide
    Muro, Kei
    Hayashi, Hidetoshi
    Shimada, Yasuhiro
    Takahari, Daisuke
    Taku, Keisei
    Nakajima, Takako Eguchi
    Shi, Xiaojin
    Brown, Kathryn H.
    Boku, Narikazu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 439 - 446
12345